

RESEARCH ARTICLE

Protective Effect of *Echinacea purpurea* Plant Extract Against Pasterullosis in Rabbits: Hematological, Biochemical and Oxidative Stress Studies

Nasr A M Nasr El-Deen¹, Rasha T M Alam¹, Ibtisam M Gamal El- Din², Noha G A E Sakr^{3*}

¹ Department of Clinical Pathology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Sharkia, Egypt.

² Department of Clinical Pathology, Animal Health Research Institute (AHRI), Zagazig 44511, Sharkia, Egypt.

^{3*} Department of Clinical Pathology, Animal Health Research Institute (AHRI), Mansoura, Egypt.

*Corresponding author: moonmostafa2000@gmail.com

Abstract

Echinacea purpurea (*E. Purpurea*), as one of the most important plants, has been used in prevention and control of infectious diseases of respiratory systems. In this study, we investigated the effect of *Echinacea* and enrofloxacin on *Pasteurella multocida* type A infection in male white New Zealand rabbits through evaluation of the hematological, biochemical, phagocytic activities, and oxidative stress markers. Forty male white New Zealand rabbits were divided into four equal groups; group 1 was kept as a control, group 2 was intranasally infected with *P. multocida* type A (4×10^7 CFU/mL/rabbit) at the 14th day from beginning of experiment (FBE), group 3 was administered *E. Purpurea* orally (130mg/kg body weight "B.W.") day after day from 1st day to the 35th day and infected with *P. multocida* at the 14th day FBE and group 4 was intranasally infected with *P. multocida* at the 14th day FBE, then treated with enrofloxacin (10 mg / kg B.W. in drinking water) after the appearance of the clinical signs from the 18th-20th day. The results revealed that *P. multocida* infection in rabbits produced macrocytic hypochromic anemia (RBCs = $5.26 \times 10^6/\mu\text{L}$, MCV = 76.06 fl, MCHC = 24.99%), leukocytosis ($14.09 \times 10^3/\mu\text{L}$) with a reduction in the phagocytic percent (51.60 %) and phagocytic index (0.26). We observed decrease in serum levels of total protein, albumin, and globulin. Moreover, significant increase in serum alanine aminotransferase (ALT, 34.4 U/L) and alkaline phosphatase (ALP, 27.80 U/L) were recorded. Also, the serum bilirubin (total bilirubin = 1.03mg/dL, direct bilirubin = 0.61 mg/dL and indirect bilirubin = 0.42 mg/dL) levels were significantly elevated. Serum urea (47.32mg/dL) and creatinin levels (2.10 mg/dL) were significantly increased. Furthermore, *P. multocida* infection in rabbits induced oxidative stress, which observed in a significant reduction in the serum catalase (CAT, 3.13 nmol/L) with elevation in the lipid peroxidation (MDA, 3.46 nmol/L). In conclusion, *Echinacea* treatment before and after rabbit infection with *P. multocida* type A is able to ameliorate the alterations in all studied parameters compared to enrofloxacin treated rabbits.

Key words: Rabbits, *Echinacea purpurea*, Enrofloxacin, *Pasteurella multocida*, Oxidative stress.

Introduction

Echinacea purpurea is one of the most important medicinal herbs of the genus *Echinacea* [1]. It is a purple cone flower that is widely used as a medicinal plant in the United States and Europe. The main active principles are alkaloids, glycoproteins, caffeic acid derivatives and

polysaccharides. *Echinacea purpurea* has immunostimulatory, immunomodulator, antibacterial, anti-inflammatory, wound healing, antiseptic and antineoplastic properties and growth promoting effects. Moreover, it has some short term effects against herpes, vesicular stomatitis and influenza viruses [2- 7]. *Echinacea*

improves the immunity, decreases the blood sugar levels, anxiety, and inflammation. Also, it has anti-cancer and skin health improvement effects as well as it was documented to be effective in prevention and complex treatment of Corona virus [8]. *Echinacea purpurea* (*E. Purpurea*) is one of the most promising herbal medicine for improving the immunity of various species of animals and humans [9].

Enrofloxacin is the first fluoroquinolone of second generation quinolones [10]. It acts by inhibiting the DNA gyrase, which is essential for the coiling and uncoiling of bacterial DNA and packing it within the cell [11]. Enrofloxacin is indicated for the treatment of bacterial infections of the alimentary and respiratory tracts; it is rapidly distributed through the tissues before being eliminated [12].

Pasteurellosis is a common and highly contagious disease in domestic rabbits that transmitted by direct contact and aerosol transmission. It is characterized by high morbidity and mortality rates [13]. About 30–90% of apparently healthy rabbits may be a symptomatic carrier [14]. It is one of the main causes of economic losses in rabbits [15]. *Pasteurella* infection is depending on age and stress factors [16]. It has three forms in rabbitaries in Egypt. The 1st one is, subacute form during first two days post infection (PI). This form manifested by drowsiness, sneezing, pyrexia and anorexia. In the third day, they became off food with lacrimation and mild diarrhea. In the later stages, infected rabbits showed dullness, emaciation, coughing and breathing with a sound "snuffling". Also nasal discharge became turbid and sticky [17]. The subclinical infection was established in the upper respiratory tract. After colonization, the infection extends to the rest of respiratory tract and can cause clinical rhinitis, conjunctivitis, pneumonia, tracheitis or

otitis media [14]. The 2nd form is characterized by abscess formation at any part in the body and the case is terminated with septicemia [18]. Otitis media or interna form includes accumulation of pus or fluid in the middle or inner ear, so the rabbit twist its head e.g "wry neck" or torticollis. Also, subcutaneous and visceral abscesses may be clinically silent for long periods and spontaneously rupture [19]. The third form manifested by urogenital infection, mastitis, pyometra, orchitis, infertility, abortion and meningitis [20].

This study aimed to investigate the efficacy of *E. Purpurea* plant and enrofloxacin in controlling *P. multocida* experimental infection in rabbits.

Material and Methods

Experimental animals

A total number of forty, 30 days old, apparently healthy male white New Zealand rabbits (750-1000g) were purchased from the Faculty of Agriculture, Zagazig University, Egypt. These rabbits were kept under good hygienic conditions, housed in clean metal cages, kept at 24 ± 2 °C with a 50–60% humidity and a 12-hour light:dark cycle, fed on well balanced commercial ration and water was provided *ad-libitum*. Rabbits were kept for 2 weeks before starting the experiment. The management and treatment procedures were done according to the Guidelines for the Care and Use of Laboratory Animals of the National Institutes of Health

Chemical treatment agents

Enrofloxacin (Opitryl) was manufactured by El-Obour Modern Pharmaceutical Industries Co, Egypt. Each 100 mL contains 10g enrofloxacin, it was given as a 10% oral solution. *Echinacea purpurea* dry extract capsules (each one contains 175mg) were purchased from Arab Company for

Pharmaceuticals and Medicinal Plants, Purpureaco-Egypt. All the biochemical tests were performed using test kits of Diamond Diagnostics, Egypt.

Bacterial strain

Pasteurullamultocida type strain C51-17 (capsular type A) was obtained from the Animal Health Research Institute, Dokki, Giza, Egypt. Rabbits were infected intranasally by a dose of 1mL with a final concentration of 4×10^7 colony forming unit (CFU).

Experimental design

Forty apparently healthy male, white New Zealand rabbits, were randomly classified into four equal groups (each group contains 10 rabbits). Group 1 was given 1 mL phosphate buffer saline (PBS) intranasal (IN) and kept as a negative control. Group 2 was infected with *P. multocida* type A (4×10^7 CFU/mL/rabbit) at the 14th day [21], from the beginning of the experiment (FBE) (a positive control). Group 3 was orally administered *E. purpurea* (130 mg/kg B.W.) day after day [22] from 1st day to the 35th day and infected with the above mentioned dose of *P. multocida* type A at 14th day FBE. Group 4 was infected IN with *P. multocida* type A at the 14th day, and treated with enrofloxacin (10mg/kg B.W.), orally by gavage for 3 days after the appearance of the clinical signs [23].

Samples collection and preparation

Blood samples were collected from 3 rabbits in each group under anesthesia on the 35th day FBE from the ear vein. Two mL of the blood was collected in a heparinized test tube for evaluation of phagocytic activities, 0.5mL of the blood collected in a test tube with ethylene diamine tetra acetic acid (EDTA) for hematological examination, and 5mL was collected in serum separation glass tube without anticoagulant to measure biochemical parameters.

Hematological assay

Collected blood samples on EDTA (10%) were used for the evaluation

of total erythrocyte count, packed cell volume (PCV), hemoglobin (Hb), white blood cells (WBC) and differential leukocyte counts (DLC) according to Coles [24]. Mean corpuscular volume (MCV) and mean corpuscular hemoglobin concentration (MCHC) values were calculated.

Phagocytic percent and index

The heparinized blood samples were used for leukocytes separation. *Candida albicans* (*C. albicans*) was prepared at Animal Health Research Institute Zagazig and used for determination of the phagocytic activity according to Wilkinson [25]. Macrophages (monocytes and lymphocytes) number containing *C. albicans* (phagocytic %) that were engulfed by 100 phagocytes in each individual preparation was examined under light microscope under oil immersion lens. The phagocytic index was calculated through evaluating the average number of attached and ingested *C. albicans* multiplied by the phagocytic % [26].

Biochemical assay

Serum samples were analyzed for determination of alanine aminotransferase (ALT) by the method of Reitman and Frankle [27] and alkaline phosphatase (ALP) according to a previously published protocol [28]. Total protein and albumin levels were measured described elsewhere [29,30]. The globulin level was calculated by subtracting the obtained albumin level from obtaining total protein level according to Doumas and Biggs [31]. Serum bilirubin (total and direct) was determined according to Colombo [32] and the indirect bilirubin level was calculated as the difference between total and direct bilirubin. Urea and creatinine were determined documented previously [33, 34].

Oxidative stress markers assay

Serum samples were used to determine the catalase (CAT) activity which was measured by an enzymatic colorimetric method using ready-made kits provided by Biodiagnostic Egypt, CAT. No. CAT 25 17 according to Aebi [35], and lipid peroxidation (MDA) was determined depending on the thiobarbituric acid reactivity of *Satoh* [36], CAT. No. 25 29.

Statistical Analysis

The obtained data was statistically analyzed using "F" test one way ANOVA according to Tamhans and Dunlop (37) using "MSTAT-C" computer program. Means in the same column followed by different letters were statistically significant at $P < 0.05$ and the highest values were represented with the letter (a).

Results

Clinical signs and mortality rate

Negative control rabbits appeared healthy without any clinical signs of illness and no mortalities were recorded. On the other hand, rabbits in positive control group showed ruffled fur, sneezing, nasal discharge, purulent exudates from nose, abnormal respiratory sound and mortality rate reached 60%. Both rabbits treated with *Echinacea purpurea* and enrofloxacin then infected with *P. multocida* showed mild clinical signs with mortality rates of 33.33% and 20% in groups 3 and 4, respectively.

Hematological findings

Rabbits infected with *P. multocida* showed a significant decrease ($P < 0.05$) in RBCs count, Hb concentration, PCV and MCHC, with a significant increase in MCV (macrocytic hypochromic anemia) compared with the control. While rabbits infected and treated

with *E. purpurea* and enrofloxacin showed improvement in RBCs count, Hb concentration, PCV and MCHC with significant decrease ($P < 0.05$) in MCV in comparison with infected rabbits (Table 1).

In comparison to negative control rabbits, infected rabbits showed a significant increase ($P < 0.05$) in the counts of leukocytes, granulocytes and monocytes with non-significant change in lymphocytic count. While *E. purpurea* and enrofloxacin treated rabbits showed a significant decrease ($P < 0.05$) in total leukocytes counts, granulocytic count and monocyte count with non-significant change in lymphocyte count when compared to the infected group (Table 2). Moreover, *P. multocida* infected rabbits showed a significant decrease ($P < 0.05$) in phagocytic percent and phagocytic index compared to control negative rabbits, while *E. purpurea* and enrofloxacin treated rabbits showed a significant increase ($P < 0.05$) in phagocytic percent and phagocytic index comparing with infected rabbits (Table 2).

Biochemical findings

Serum activities of ALT, ALP and bilirubin (total, direct and indirect) levels showed a significant increase ($P < 0.05$) in rabbits infected with *P. multocida* compared to the negative control, while treated groups 3 and 4 showed a significant decrease ($P < 0.05$) in serum ALT, ALP activities and bilirubin levels when compared to infected rabbits (Table 3). Serum urea and creatinine levels showed a significant increase ($P < 0.05$) in group 2 compared with the negative control, while groups 3 and 4 showed a significant decrease ($P < 0.05$) compared with the infected group (Table 4).

Antioxidant and oxidative stress findings

Rabbits infected with *P. multocida* showed a significant increase ($P < 0.05$) in serum CAT activity and significant decrease ($P < 0.05$) in MDA level compared to the negative control.

While rabbits treated with *E.purpura* and CAT activity with a significant enrofloxacin (groups 3 and 4) showed a decrease ($P < 0.05$) in MDA level significant increase ($P < 0.05$) in serum compared to infected rabbits (Table 5).

Table (1): Erythrogram (mean value \pm SE) of rabbits' groups at the 35th day from the beginning of the experiment.

Groups	Parameters					
	RBCs Count $\times 10^6/\mu\text{L}$	Hb g/dL	PCV %	MCV Fl	MCH pg	MCHC (%)
GP1 (Control)	6.48 ^a ± 0.30	12.50 ^a ± 0.37	43.15 ^a ± 0.98	66.92 ^b ± 1.04	19.38 ^a ± 0.13	28.96 ^a ± 0.27
GP2 (<i>P.multocida</i>)	5.26 ^b ± 0.14	10.00 ^c ± 0.33	40.00 ^b ± 0.85	76.06 ^a ± 1.83	19.00 ^a ± 0.46	24.99 ^b ± 0.14
GP3 (<i>Echinacea</i> + <i>P.multocida</i>)	6.10 ^a ± 0.18	12.00 ^{ab} ± 0.48	42.00 ^{ab} ± 1.00	68.85 ^b ± 0.88	19.67 ^a ± 0.15	28.57 ^a ± 0.15
GP4 (<i>P.multocida</i> +Enrofloxacin)	6.21 ^a ± 0.22	12.20 ^a ± 0.23	42.70 ^a ± 0.24	68.76 ^b ± 0.60	19.46 ^a ± 0.37	28.57 ^a ± 0.92

Means within the same column carrying different letters are significantly different at $P < 0.05$

RBCs Count : Red blood cell count; MCV : Mean corpuscular volume; Hb: Hemoglobine; MCH: Mean Corpuscular Hemoglobin; MCHC: Mean Corpuscular Hemoglobin Concentration; Fl : femtoliters (one thousand trillionths of a liter) per/cell; PCV: Packed Cell Volume; pg: picograms/ cell (one trillionth of a gram); $\times 10^6/\mu\text{L}$: millions of cells per microliter; g/dL: grams per deciliter

Table (2): Leukogram and phagocytic activity (mean value \pm SE) of rabbits' groups at the 35th day from the beginning of the experiment.

Groups	TLC ($\times 10^3/\mu\text{L}$)	Differential leukocytic count			Phagocytic %	Phagocytic Index
		Granulocytes ($\times 10^3/\mu\text{L}$)	Lymphocytes ($\times 10^3/\mu\text{L}$)	Monocytes ($\times 10^3/\mu\text{L}$)		
GP1 (Control)	12.74 ^b ± 0.12	5.63 ^b ± 0.11	6.56 ^a ± 0.29	0.55 ^b ± 0.02	59.30 ^a ± 1.76	0.60 ^a ± 0.04
GP2 (<i>P.multocida</i>)	14.09 ^a ± 0.17	6.80 ^a ± 0.03	6.43 ^a ± 0.21	0.85 ^a ± 0.06	51.60 ^b ± 0.88	0.26 ^c ± 0.03
GP3 (<i>Echinacea</i> + <i>P.multocida</i>)	13.14 ^b ± 0.14	6.00 ^b ± 0.09	6.56 ^a ± 0.11	0.58 ^b ± 0.03	60.12 ^a ± 0.44	0.50 ^{ab} ± 0.08
GP4 (<i>P.multocid</i> +Enro floxacin)	12.89 ^b ± 0.16	5.80 ^b ± 0.17	6.54 ^a ± 0.13	0.55 ^b ± 0.05	58.25 ^a ± 1.06	0.51 ^{ab} ± 0.14

Means within the same column carrying different letters are significantly different at $P < 0.05$, TLC : Total Leukocytic Count, $\times 10^3/\mu\text{L}$: Thousand per microliter

Table (3): Some serum biochemical parameters (mean value \pm SE) of rabbits' groups at the 35th day from the beginning of the experiment.

Groups	Parameters				
	ALT U/L	ALP U/L	Total bilirubin mg/dL	Direct bilirubin mg/dL	Indirect bilirubin mg/dL
GP1 (Control)	23.60 ^c ± 0.45	18.80 ^c ± 0.25	0.56 ^c ± 0.02	0.31 ^{cd} ± 0.01	0.25 ^c ± 0.01
GP2 (<i>P.multocida</i>)	34.40 ^a ± 0.87	27.80 ^a ± 0.72	1.03 ^a ± 0.06	0.61 ^a ± 0.04	0.42 ^a ± 0.03
GP3 (<i>Echinacea</i> + <i>P.multocida</i>)	27.20 ^b ± 0.55	21.00 ^b ± 0.30	0.82 ^b ± 0.03	0.41 ^b ± 0.02	0.35 ^b ± 0.01
GP4 (<i>P.multocida</i> +Enrofloxacin)	24.10 ^c ± 0.95	20.00 ^{bc} ± 0.28	0.62 ^c ± 0.05	0.35 ^{bc} ± 0.02	0.27 ^c ± 0.02

Means within the same column carrying different letters are significantly different at $P < 0.05$

ALT: Alanine transaminase, mg/dL: milligramper deciliter, ALP: Alkaline Phosphatase U/L: international units/liter.

Table (4): Some renal function tests (mean value \pm SE) of rabbits' groups at the 35th day from the beginning of the experiment.

Groups	Urea mg/dL	Creatinine mg/dL
GP1 (Control)	38.60 ^c ± 0.32	1.10 ^c ± 0.05
GP2 (<i>P.multocida</i>)	47.32 ^a ± 0.58	2.10 ^a ± 0.04
GP3 (<i>Echinacea</i> + <i>P.multocida</i>)	41.50 ^b ± 0.28	1.52 ^b ± 0.04
GP4 (<i>P.multocida</i> +Enrofloxacin)	39.50 ^c ± 0.38	1.25 ^c ± 0.09

Means within the same column carrying different letters are significantly different at $P < 0.05$

mg/dL: milligram /deciliter

Table(5): Serum catalase and malondialdehyde (mean value \pm SE) of rabbits' groups at the 35th day from the beginning of the experiment.

Groups	CAT (nmol/L)	MDA (nmol/L)
GP1 (Contro)	4.56 ^a ± 0.32	1.86 ^b ± 0.19
GP2 (<i>P.multocida</i>)	3.13 ^b ± 0.17	3.46 ^a ± 0.23
GP3 (<i>Echinacea</i> + <i>P.multocida</i>)	4.30 ^a ± 0.24	2.04 ^b ± 0.05
GP4	4.36 ^a	2.00 ^b

(P.multocida+Enrofloxacin)

±0.14

±0.13

Means within the same column carrying different letters are significantly different at $P < 0.05$

CAT : Catalase, MDA: Malondialdehyde, (nmol/L) : Nanomoles Per Liter

Discussion

Pasteurella multocida is the most common bacterial pathogen in rabbits. Stress, such as shipping, mating and handling, may cause replication of many serotypes of *P. multocida*. Depression, in appetite, rhinitis, sneezing, coughing, nasal discharge, conjunctivitis, breathing with a snuffling sound, pneumonia and torticollis were recorded in *P. multocida* infected rabbits, that attributed to the infection with pathogen via respiratory route causing inflammation of mucous membranes before spreading through blood [14, 16, 19, 20 and 38]. The high mortality rate was recorded in the infected rabbits that resulted from the side effect of *P. multocida* endotoxin [15, 17]. Severity of clinical signs and mortality rates was improved in the treated groups (3, 4), which mainly attributed to the presence of alkaloids, tannins and sterols or total phenols and flavonoids in the *E. purpurea* that have antimicrobial activity [39] and the antibacterial activities of enrofloxacin [40].

Concerning the erythrogram, *P. multocida* infected rabbits exhibited a significant reduction in RBCs count, Hb concentration and PCV % with the development of macrocytic hypochromic anemia that attributed to the hemorrhagic effect of the bacteria and/ or its endotoxin on RBCs, which led to reduce their life span which stimulate active erythropoiesis that led to reticulocytosis. Our data supported the previously obtained results by Praveena and coauthors [41]. Rabbits protected and treated with *E. purpurea* before and after *P. multocida* infection (group 3) showed an improvement in the erythrogram. This indicates that using *E. purpurea* as prophylactic and treatment is more effective in protect the cells [42, 43]. Enrofloxacin treated rabbits (group 4)

also showed an improvement in the erythrogram due to the effectiveness of this antibiotic against *P. multocida*.

Leukocytosis was observed in rabbits infected with *P. multocida* due to heterophilia and monocytosis. Such elevation in heterophils and monocytes counts could be due to the infection and inflammation [24]. Heterophiles and monocytes counts were reduced in rabbits treated with *E. purpurea* before and after infection with *P. multocida* due to anti-inflammatory and antibacterial effect of *E. purpurea* [44]. Also, there was an improvement in the total leucocytic count, heterophils and monocytes in enrofloxacin treated rabbits.

Rabbits infected with *P. multocida* revealed a reduction in the phagocytic percent and phagocytic index, which attributed to the effect of oxidative stress that exhaust the body immune response resulted from infection and /or *P. multocida* endotoxin [45]. Phagocytosis was inhibited by *P. multocida* capsular polysaccharides [46]. While, rabbits treated with *E. purpurea* revealed a significant improvement in the phagocytic percent and index, attributed to the glycoprotein rich fractions of *E. purpurea* that enhances the phagocytic activity [47, 48], also the immune-stimulatory effects of lipophilic alkylamides, polar caffeic acid derivative and cichoric acid of *E. purpurea* [49, 50]. The improvement of phagocytic percent and index was recorded in enrofloxacin treated rabbits due to the effectiveness of this antibiotic against *P. multocida* so reduces its negative impact on phagocytic percent and index.

Regarding to the biochemical results, rabbits infected with *P. multocida* showed reduction in the total protein and albumin with an elevation of globulin levels, which

may be due to a reduction in feed intake by diseased animal and / or protein synthesis by damaged liver. Also, it may be due to increase protein loss nephropathy [14]. While the hyperglobulinemia indicated the immune defense of rabbits due to respiratory infection and increase the level of antibodies to combat this infection [51, 52]. Hepatic enzymes (ALT and ALP) significantly elevated in the infected rabbits [53], such elevation in ALT activity due to the hepatocellular damage resulted from the infection and subsequent liberation of these enzymes from damaged hepatocytes into the circulation, also serum ALP elevation is associated with cholestasis [54].

Rabbits received *E.purpurea* before and after *P.multocida* infection showed an elevation in the protein level with reduction in serum activities of ALT and ALP that attributed to the hepato-protective effect of *Echinacea* [7 and 55], also *Echinacea* species stimulate the immune response of the body [56]. Moreover, rabbits treated with enrofloxacin showed a significant improvement in the total protein, albumin, globulin and hepatic enzymes. Fluoroquinolones act by interfering with bacterial DNA synthesis so preventing the growth and replication of *P.multocida* [57] reducing the damaging effect of it. Furthermore, serum total, direct and indirect bilirubin were elevated in infected rabbits, that attributed to hepatocellular damage resulted from the effect of *P.multocida* and/or its toxin on hepatocytes [17]. Thus, all major excretory steps of bilirubin may be distributed and resulted in an elevation in total bilirubin [54], these findings agree with Glavits and Magyer [58]. Administration of *E.Purpurea* before and after *P.multocida* infection induced reduction in total, direct and indirect bilirubin, which attributed to the presence of large amount of chicoric acid and caftaric acid in *E.Purpurea*, which had a role in inhibition of hyaluronidase enzyme, that secreted by bacteria to facilitate

penetration into tissue [59], so treatment with *E.Purpurea* protect hepatic cell and reduce the elevated bilirubin [55]. Moreover, using enrofloxacin could counteract the effect of *P. multocida* and reduce the level of bilirubin.

Concerning the kidney function tests, *P.multocida* infected rabbits exhibited a significant elevation in the levels of serum urea and creatinine levels, which attributed to the renal damage induced by *P. multocida* and /or its endotoxin on renal tissue. Also, the circulating toxin may lead to reduce the renal blood flow and glomerular filtration rate leading to accumulation of serum nitrogenous end products [60], our results run on the same ground with those reported by Gaber [15].

Rabbits administered *E.purpurea* before and after infection revealed amelioration of renal function, which confirms the ability of *E.purpurea* to protect the renal tissue against infection and toxins due to its high content of natural metabolites that have antibacterial activity [61], also the alkaloid content of *E.Purpurea* down regulates inflammatory responses in the tissue [62]. Our results are in accordance with previously published researches [54, 63]. Moreover, enrofloxacin administered rabbits showed improvement in the serum urea and creatinine levels, which attributed to its antibacterial activity, which suppress bacterial infection and decreasing the damaging effect on the kidney [64].

Concerning the oxidative stress marker evaluation, infected rabbits showed a significant reduction in serum activity of CAT with elevation MDA level. From our opinion, this may be due to endotoxin effect of *P.multocida* which increased the oxidative stress and exhausting the antioxidant defense system, leading to decrease of CAT enzyme and increase of lipid peroxidation [37 and 65]. Rabbits treated with *E.purpurea* showed a significant elevation in the serum CAT level with the reduction MDA level,

which may be due to the natural components found in *E.purpurea* (echinacoside, caffeic acid, total phenols, and flavonoid), which have antioxidant activities by elimination of free radicals and subsequently prevent destruction of cell [7, 39,66, 67, 68] and the alkaloid contents decreases the proinflammatory cytokines and TNF-alpha [62]. Enrofloxacin improved the antioxidant status of infected rabbits through its ability to reduce bacterial replication, as it is effective against *p. multocida* infection, so reduces the oxidative stress resulted from infective microorganism and its toxin.

Conclusion

Our results indicate that using of *Echinacea* for prophylactic and treatment of *Pasteurella* infection returned the altered hematological, biochemical and oxidative stress markers nearly to the normal.

Conflict of Interest

The authors have no conflict to declare.

Reference

- [1] Bauer, R. and Wagner, H. (1991): *Echinacea* species as potential immunostimulatory drugs. In: Wagner H and Farnsworth N R (Eds.), Economic and Medicinal Plant Research, London Academic Press Limited, 5: 253–321.
- [2] Thomson, P. D. R. (2004): Physicians Desk Reference (PDR for herbal medicines). 3rd ed. Montval N J., 267-71, 650 - 51.
- [3] Ahmed, H .S.; Kamel, K. I.; El-Sabeiy, M .E. and Zeitouny, M.H .(2008): Effect of *Echinacea* extract supplementation on growth performance and hemobiochemical traits of growing rabbits. Egypt PoultSci, 28(4):1165-80.
- [4] Manayi, A.; Vazirian, M .and Saeidnia, S. (2015): *Echinacea purpurea*: Pharmacology, phytochemistry and analysis methods. Phcog Rev. 9:63.
- [5] Sharma, P.; Kumar, P.; Sharma, R.; Gupta, G. and Chaudhary, A. (2017): Immunomodulators: Role of medicinal plants in immune system. Natl J Physiol Pharm Pharmacol. 7:552.
- [6] Abu Khudir, R.; El-Magd, M.A.; Salama, A.F.; Tousson, E.M. and El-Dsoki, S.M. (2019): Curcumin Attenuated Oxidative Stress and Inflammation on Hepatitis Induced by Fluvastatin in Female Albino Rats. Alex J of Vet Scie: 62, 102-115.
- [7] Ibrahim, A.A.; Saleh, R.M.; Hassan, A.E. and Amer, M.S. (2020): Ameliorative effect of *Echinacea purpurea* and curcumin on dexamethasone-induced immunosuppressive rabbits. Kafrelsheikh Veterinary Medical Journal (KVMJ), 18(1):10-16.
- [8] Miroshina, T. and Poznyakovskiy, v. (2023): *Echinacea purpurea* as a medicinal plant: characteristics, use as a biologically active component of feed additives and specialized foods (review). International Conference "Scientific and Technological Development of the Agro-Industrial Complex for the Purposes of Sustainable Development" (STDAIC-2022), Bishkek, Kyrgyzstan, Edited by Shergaziev, U.A.; Laamarti, Y.A.; E3S Web of Conferences, Volume 380, id.01005.
- [9] Bagno, O.; Shevchenko, S. and Shevchenko, A. (2021): *Echinacea purpurea* extract efficiency in growing broiler chickens. Ach of Sci and Tech APK. 35(2). 61-65.
- [10] Hsu, H.M.; Stofregen, D.A.; Wooster, G.A. and Bowser, P.R. (1993): Target animal safety studies of enrofloxacin in fingerling rainbow trout (*Oncorhynchus mykiss*). Bull. Euro. Ass. Fish Path., 13(4): 141-143.
- [11] Michel, C.; Kerouault, B. and Martin, C. (2003): Chloramphenicol and florfenicol susceptibility of fish-pathogenic bacteria isolated in France: comparison of minimum inhibitory concentration, using recommended provisory standards for

- fish bacteria. *J. Appl. Microbiol.* 95, 1008-1015.
- [12] Broome, R.L.; Brooks, D.L. and Babish, J.G. (1991): Pharmacokinetic properties of enrofloxacin in rabbits. *Am JVetRes.*,52:1835-1841.
- [13] Mahmoud, S.A.G. and Abdel Baset, L.E.M. (1991): An outbreak of pasteurellosis at Kalubia province. *Egypt. Zag. Vet. J.*, 19 (2): 499-510.
- [14] Harcourt-Brown, N. (2002): Text book of rabbit Medicine. 1st edition, Butterworth-Heinemann.Oxford, Auckland, Boston, Johannesburg, Melbourne, New Delhi. P:105-286.
- [15] Gaber, A.A.M. (2016): Clinicopathological studies on the effects of azithromycin in rabbits. Thesis for degree of Master (Clinical Pathology); Fac.Vet. Med; Zag Univ.
- [16] Awad, N.F.S. (2013): Some Studies on Rabbit Pasteurellosis. PH.D. Thesis (Poultry and Rabbit diseases), Fac. Vet. Med. Zag. Univ.
- [17] Heba, E.M.R (2015): Clinicopathological studies on some antibiotics. Thesis for degree of master (Clinical Pathology); Fac.Vet. Med; Zag Univ.
- [18] Sandford, J. (1996): Domestic rabbit. 5th edition. Granada Publishing, London, UK.
- [19] Kahn, C.M. (2011): The Merck Veterinary Manual, Tenth edition New Jersey USA.
- [20] Lennox, A.M. and Kelleher, S. (2009): Bacterial and parasitic diseases of rabbit. *Veterinary Clinics of North America*, 12(3):519-530.
- [21] Allam, E.Y.E. (1992): Bacteriological studies on pasteurellainfection in rabbits in Kaluobia governorate. A thesis for the degree of master in Veterinary Science. Faculty of Vet. Med Moshtohor, Dep.of Microbiology, Benha branch, Zagazig University.
- [22] Omar, A.A.F. (2010): Some physiological and neurological parameter as affected by Echinacea purpurea extract on rabbits. Thesis (Department of Animal Production), Faculty of Agriculture Cairo University.
- [23] Okerman, L. ;Devriese, L.A. and Gevaert, D. (1990): In vivo activity of orally administered antibiotics and chemotherapeutics against acute septicaemicpasteurellosis in rabbits. *Lab .Anim.*, 24 :341-344.
- [24] Coles, H.E. (1986): Veterinary Clinical Pathology. Fourth edition. W.E. Saunders Company Philadelphia, London, Toronto, Mexico city, Rio De Janeiro, Sydney, Tokyo, Hong Kong.
- [25] Wilikinson, P.C. (1977): Recognition and response in mononuclear and granular phagocytes. *Clin. Exp. Immunol.*, 25 (3): 255-366.
- [26] Muniz-Junqueira, M . I. ;Prata,A. and Tosta, C . E. (1992): Phagocytic and bactericidal function of mouse macrophages to Salmonella typhimurium in schistosomiasis mansoni , *AM J Trop Med Hyg* 46(2):132-6.
- [27] Reitman, S. and Frankle, S. (1957) :Coloremetric method for determination of serum transaminase activity. *Am. J. Clin. Path.* 28.
- [28] Kind, P. R. N. andKing, E. G.(1954) : Colorimetric determination of alkaline phosphatase activity. *J Clin Pathol*, 7:322.
- [29] Doumas,B . T.; Watson, W . A.and Biggs, H.G. (1971): *Clin Chem Acta*, 31:87-96.
- [30] Drupt, F. (1974) : Colorimetric determination of albumin. *Pharm. Biol.*, 9: 777.
- [31] Doumas, B. and Biggs, H.G. (1972): Determination of serum globulin in : *Standard Methods of Cilnical Chemistry* Vol. 7. Edited by Cooper, New York, Academic Press.
- [32] Colombo, G. (1974) : Determination of bilirubin with single reagent using diazotized dichloroaniline. *Clin.Chem. Acta.*, 51:217.
- [33] Kaneko, J. (1984): *Clinical biochemistry of domestic animals*. 4th Ed. Academic press, San Diego, New York, Toronto, London, Tokyo.

- [34] Henry, T. J. (1974) : Determination of serum creatinine. Clin. Chem. Principles and Techniques. 2ndEd., Harper and Row Publishers. New York.
- [35] Aebi, H. (1984): Catalase in vitro. Methods Enzymol, 105; 121-26.
- [36] Satoh, K. (1978): Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin. Chem. Acta, 90:37-42.
- [37] Tamhans A F and Dunlop D D (2000) : Statistics and Data Analysis from Elementary to Intermediate. Upper Saddle River, USA.
- [38] Nakagawa, M.; Nakagawa, K.; Aito, M.; Takayama, S. and Watarai, S. (1986): Bacteriological and serological studies on pasteurized rabbit sera. Exp. Anim., 43(4):463-469.
- [39] Stanisavljevi, I.; Stojievi, S.; Veli kovi, D.; Veljkovi, V. and Lazi, M. (2009): Antioxidant and Antimicrobial Activities of Echinacea (Echinacea purpurea L.) Extracts Obtained by Classical and Ultrasound Extraction. Biotechnology and Bioengineering Chinese Journal of Chemical Engineering, 17: (3) 478-83.
- [40] Abd al-Hamid, M.I.S. Abd al-Aziz, S.M.A. and Mursi, U.M.M.M. (2009): Chemo-Therapeutic activity of gatifloxacin against haemorrhagic septicemia in rabbits. Kafrelsheikh, Vet. Med. J., 3rd Sci, Congress. 1048-1074.
- [41] Praveena, E.P.; Singh, N.; Sivakumar, P. and Kumar, A.A. (2007): Studies on haemato-biochemical changes in Pasteurella multocida serotype A:1 infection in mice, Indian J. Vet. Pathol., 31(2):155-159.
- [42] Abouelella, A.M.K.; Shahein, Y.E.; Tawfik, S.S. and Zahran, A. M. (2007): Phytotherapeutic effects of Echinacea purpurea in gamma-irradiated mice. J. Vet. Sci., 8(4):341-51.
- [43] Nematalla, K.H.M.; Arafa, S.A.; Yousef, G.M. and Shabib, Z.A. (2011): Effect of Echinacea as antioxidant on markers of aging. Australian Journal of Basic and Applied Sciences, 5:18-26.
- [44] Thomson, P.D.R. (2004): Physicians Desk Reference (PDR for herbal medicines). 3rd ed. Montval N J., 267-71, 650 - 51.
- [45] Salvador, A.; Juan, J.B.; Irene, Z.; Maria, C.B. and Miguel, A. M. (1998): Role of the capsule of Photobacterium damsela subsp. piscicida in protection against phagocytosis and killing by gilt-head seabream (Sparus aurata, L.) macrophages. Department of Microbiology, Faculty of Sciences, University of Malaga, Fish & Shellfish Immunology., 8: 63-72.
- [46] Ruehl, W.; Hinojoza, J.; Murray, W.; Rush, H. and Marrs, C. (1991): Identification and immunologic evaluation of a putative pilin in Pasteurella multocida. AALAS Bull 30:21.
- [47] Melchart, D.; Linde, K.; Worku, F.; Sarkady, L.; Holzmann, M.; Jurcic, K. and Wagner, H. (1995): Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. J. Altern. Complement Med., 1:145-160.
- [48] Torkan, S.; Khamesipour, F. and Katsande, S. (2015): Evaluating the effect of oral administration of Echinacea hydroethanolic extract on the immune system in dog. Auton Autacoid Pharmacol. 35:9-13.
- [49] Bone, K. (1997): Echinacea: What makes it work? Alternative Medicine Review J. 2(2):87-93.
- [50] Gamal, A. S.A. (2013): The effect of Azithromycin, Echinacea spp. and their combination on the immune response in vaccinated rats. Ph. D. Thesis (Dept. of Pharmacology), Faculty of Vet. Medicine., Zagazig University.
- [51] Rasha, M.A. (2002): Clinicopathological studies on the effect of antibiotic (Nuflor) on diseased Domestic Rabbits. A thesis for the degree of M.V.Sc, Department of clinical pathology, Faculty of Vet. Medicine, Zagazig University.

- [52] Ibtisam, M. G. E. and Shadia, A.R. (2005): Evaluation of fosbac plus T (Phosphomycin with Tylosin) for control of Pasteurellosis in duckling. *Mansoura, Vet. Med. J. Vol. VII., 2: 69-85.*
- [53] Dwivedi, P. and Charan, K. (2001): *Pasteurella multocida*-12:A induced clinico-pathological changes in rabbits. *Indian Journal of Veterinary Pathology, 25(2):24-27.*
- [54] Kaneko, J.J. (1997): Porphyrins and the porphyrias. In: Kaneko, J.J.,; Harvey, J.J.W.; Bruss, M.L.; eds. *Clinical Biochemistry of Domestic Animals*. 5th edition. San Diego. P: 205-221.
- [55] Annahita, R.; Ali, F.; Mojtaba, H. K.; Ali, S.; Hossein, N. Z. and Marzieh P. (2013): Effect of *Echinacea purpurea* on hepatic and renal toxicity induced by diethylnitrosamine in rats. *Jundishapur. J. Natural Pharmaceutical Product, 8 (2): 60-64.*
- [56] Burger, R. A.; Torres A.R.; Warren, R. P., Caldwell, V. D. and Hughes, B. G. (1997): *Echinacea*-induced cytokine production by human macrophages. *Int. J. Immunopharmacol., 7:371- 379.*
- [57] Theoharis, C. T. (1996): *Essential of pharmacology*. Second Ed., Boston: 302-303.
- [58] Glavits, R. and Magyer, T. (1990): The pathology of experimental respiratory infection with *Pasteurella multocida* and *Bordetella bronchiseptica* in rabbits. *Acta Veterinaria Hungarica, 38 (3) : 211-215.*
- [59] Melchart, D.; Clemm, C.; Weber, B.; Draczynski T.; Worku, F., Linde, K.; Weidenhammer, W. ; Wagner, H. and Saller, R. (2002): Polysaccharides isolated from *Echinacea purpurea* herba cell cultures to counteract undesired effects of chemotherapy a pilot study. *Phytother Res J. 16:138-42.*
- [60] Radastitis, O. M. ; Blood, K. C. and Day, C. C. (1995): *Veterinary Medicine*. Ninth Ed., Bailliere, Tindall.
- [61] Sharma, S. M.; Schoop, S. R. and Hudson, J. B. (2011): The potential use of *Echinacea* in acne: control of propionic bacterium acnes growth and inflammation. *Phytotherapy research, 25:517-521.*
- [62] Guiotto, P. ; Woelkart, K. ; Grabnar, I. ; Voinovich, D.; Perissutti, B.; Invernizzi, S. ; Granzotto, M. and Bauer, R. (2008) Pharmacokinetics and immunomodulatory effects of phytotherapeutic lozenges (bonbons) with *Echinacea purpurea* extract. *Phytomedicine, 15(8):547-54.*
- [63] Hashem, M.A.; Neamat-Allah, A.N.F.; Hammza, H.E.E. and Abou-Elnaga, H.M. (2019): Impact of dietary supplementation with *Echinacea purpurea* on growth performance, immunological, biochemical, and pathological finding in broiler chickens infected by pathogenic *E. coli*. *Trop anim health pro. 12:1-9.*
- [64] Hwang, Y.H.; Yang, H.J. ; Kim, D. G. and Ma, J.Y. (2017): Inhibitory effects of Multiple dose treatment with baicalein on the pharmacokinetics of ciprofloxacin in rats. *Phytother RES; 31(1): 69-74.*
- [65] El-Deeb, W. and Tharwat, M. (2015): Lipoproteins profile, acute phase proteins, proinflammatory cytokines and oxidative stress biomarkers in sheep with pneumonic pasteurellosis. *Comparative Clinical Pathology., 24: 581-588.*
- [66] Bauer, R. (1996): *Echinacea* drugs, effects and active ingredients. *Z Aertzt Fortbild (Jena), 90:111-15.*
- [67] Mishima, S.; Saito, K.; Maruyama, H.; Inoue, M.; Yamashita, T.; Ishida, T. and Gu, Y. (2004): Antioxidant and immunoenhancing effects of *Echinacea purpurea*. *Biol. Pharm. Bull., 27(7):1004-09.*
- [68] Sharma, M.; Schoop, R. and Hudson, J. B. (2009): *Echinacea* as an antiinflammatory agent: the influence of physiologically relevant parameters. *Phytother Res. 23:863-7.*

الملخص العربي

التأثير الوقائي لنباتات الإشنسا على خلايا الدم وكيمياء الدم والقدرة على الإلتهاام ومضادات الأكسدة في الأرانب المعدية تجريبيا بالباستيريلا مالتوسيدا.

- نصر عبد الوهاب محمد¹، رشا ثابت متولى علام¹، إيتسام محمد جمال الدين²، نها جمال أمين المتولصقر³*
- 1- قسم الباثولوجيا الإكلينيكية، كلية الطب البيطري، جامعة الزقازيق، الزقازيق، الشرقية، مصر.
- 2- قسم الباثولوجيا الإكلينيكية، معهد بحوث صحة الحيوان، الزقازيق 44511، الشرقية، مصر.
- 3- * قسم الباثولوجيا الإكلينيكية، معهد بحوث صحة الحيوان، المنصورة، مصر.

الإشنسا هي واحدة من أهم النباتات، وقد استخدمت في الوقاية والعلاج من الأمراض المعدية التي تصيب الجهاز التنفسي. في دراستنا، قمنا بدراسة تأثير الإشنسا والإنروفلوكساسين على الأرانب المعدية تجريبيا بالباستيريلا مالتوسيدا من خلال تقييم خلايا الدم وكيمياء الدم والقدرة على الإلتهاام ومضادات الأكسدة. فتم تقسيم أربعين أرنب نيوزلندي أبيض من الذكور البالغ متوسط أوزانهم (750-1000 جرام) ومتوسط أعمارهم شهر إلى 4 مجموعات متساوية، وتم الإحتفاظ بالمجموعة الأولى كمجموعة ضابطة، و المجموعة الثانية تلقت عدوى تجريبية للأرانب بالباستيريلا مالتوسيدا (1مللى تحتوى على 710x4 ميكروب حى) عن طريق الأنف فى اليوم الرابع عشر من بدأ التجربة (مجموعة ضابطة معدية)، والمجموعة الثالثة تم إعطاء نبات الإشنسا (130 ملليجرام/كيلوجرام وزن) للأرانب عن طريق الفم يوم بعد يوم من اليوم الأول وحتى نهاية التجربة وتم إجراء عدوى تجريبية بالباستيريلا مالتوسيدا (1مللى تحتوى على 710x4 ميكروب حى) عن طريق الأنف فى اليوم الرابع عشر من بدأ التجربة. والمجموعة الرابعة تم إجراء عدوى تجريبية للأرانب بالباستيريلا مالتوسيدا (1مللى تحتوى على 710x4 ميكروب حى) عن طريق الأنف فى اليوم الرابع عشر من بدأ التجربة وبعد ظهور الأعراض تم العلاج بالإنروفلوكساسين (10 ملليجرام/كيلو جرام وزن حى) فى ماء الشرب لمدة 3 أيام.

أوضحت النتائج أن عدوى الباستيريلا مالتوسيدا في الأرانب أدت إلى نقص معنوي في عدد كرات الدم الحمراء والهيموجلوبين وحجم الخلايا المضغوطة وحدوث فقر دم من النوع كبير الخلايا الناقص الصباغ وزيادة عدد الكريات البيضاء مع إنخفاض في مؤشر الإلتهاام. لاحظنا إنخفاضاً في مستويات البروتين الكلي والألبومين والجلوبولين في الدم. وعلاوة على ذلك، تم تسجيل زيادة كبيرة في إنزيم الألانين أمينو ترانسفيريز والألكالين فوسفاتيز، كما إرتفع مستوى الصفراء الكلية والمباشرة والغير مباشرة في الدم بشكل ملحوظ وتم زيادة مستويات اليوريا والكرياتينين بشكل ملحوظ. علاوة على ذلك، تسببت عدوى الباستيريلا مالتوسيدا في الأرانب في حدوث الإجهاد التأكسدي الذي أظهره إنخفاض كبير في إنزيم الكتاليز وزيادة معنوية في الملون داي ألديهيدو وجد ان علاج الإشنسا قبل وبعد عدوى الباستيريلا مالتوسيدا في الأرانب قادره على تحسين قياسات جميع العوامل المختبرة مقارنة بالأرانب المعالجة بالإنروفلوكساسين.